Over the last years, immunotherapies have shown very good results notably with the last generation of treatments combining different approaches for the treatment of melanoma and NSCLC. But despite the success and hope, these treatments generate severe adverse reactions, a high proportion of people still do not respond to immunotherapy, and their use in some pathologies are still in the preclinical phase.
Lots of efforts are made in order to increase efficacy with new targets, new formats, combination of treatments and with the development of cellular therapies targeting the immune system. All these aspects will be addressed during this one day symposium and we will benefit from the point of view of the French pharmaceutical industry.
Nicolas REYMOND firstname.lastname@example.org